XPH holdings and overlap
State Street SPDR S&P Pharmaceuticals ETF (XPH) holds 61 positions in its SPDR file of 2026-10-27. Its three largest are Veradermics Inc (MANE) at 2.86%, Xeris Biopharma (XERS) at 2.74% and Pacira BioSciences (PCRX) at 2.57%, and its ten largest make up 24.3% of the fund.
In its SPDR file of 2026-10-27, XPH is 99.9% health care by sector, with none of it in mega-cap tech or in the ten largest US companies by market value. By country, 98.0% of XPH is in the United States, 2.0% in Canada.
What does XPH hold, as of its issuer file of 2026-10-27?
Veradermics Inc is 2.86% of XPH on its own, against a median largest position of 8.6% across the 28 Health Care funds with a page here. No fund with a page here holds more MANE than XPH does, out of the 17 that hold it at all.
| Rank | Company | Weight | Weight bar |
|---|---|---|---|
| 1 | MANE Veradermics Inc | 2.86% | |
| 2 | XERS Xeris Biopharma | 2.74% | |
| 3 | PCRX Pacira BioSciences | 2.57% | |
| 4 | AMRX Amneal Pharmaceuticals | 2.51% | |
| 5 | MAZE Maze Therapeutics Inc | 2.32% | |
| 6 | LLY Eli Lilly | 2.3% | |
| 7 | VTRS Viatris | 2.3% | |
| 8 | PRGO Perrigo | 2.26% | |
| 9 | SEPN Septerna Inc | 2.2% | |
| 10 | LGND Ligand Pharmaceuticals | 2.19% | |
| 11 | RPRX Royalty Pharma | 2.18% | |
| 12 | PFE Pfizer | 2.17% | |
| 13 | ZTS Zoetis | 2.16% | |
| 14 | ANIP ANI Pharmaceuticals | 2.04% | |
| 15 | JNJ Johnson & Johnson | 2.04% | |
| 16 | OGN Organon | 2.04% | |
| 17 | INDV Indivior Pharmaceuticals | 2.02% | |
| 18 | INVA Innoviva | 2.01% | |
| 19 | DFTX Definium Therapeutics | 1.97% | |
| 20 | SUPN Supernus Pharmaceuticals | 1.97% | |
| 21 | PBH Prestige Consumer Healthcare | 1.97% | |
| 22 | ELAN Elanco Animal Health | 1.95% | |
| 23 | COLL Collegium Pharmaceutical | 1.95% | |
| 24 | MRK Merck | 1.94% | |
| 25 | BMY Bristol Myers Squibb | 1.93% | |
| 26 | HRMY Harmony Biosciences | 1.84% | |
| 27 | EWTX Edgewise Therapeutics | 1.84% | |
| 28 | OMER Omeros | 1.83% | |
| 29 | AMLX Amylyx Pharmaceuticals | 1.77% | |
| 30 | ETON Eton Pharmaceuticals | 1.76% | |
| 31 | JAZZ Jazz Pharmaceuticals | 1.73% | |
| 32 | TARS Tarsus Pharmaceuticals | 1.73% | |
| 33 | MBX MBX Biosciences | 1.7% | |
| 34 | TRVI Trevi Therapeutics | 1.62% | |
| 35 | HROW Harrow | 1.57% | |
| 36 | AMPH Amphastar Pharmaceuticals | 1.56% | |
| 37 | ELVN Enliven Therapeutics | 1.54% | |
| 38 | CORT Corcept Therapeutics | 1.53% | |
| 39 | LBRX LB Pharmaceuticals Inc | 1.45% | |
| 40 | ZVRA Zevra Therapeutics | 1.44% | |
| 41 | NUVB Nuvation Bio | 1.41% | |
| 42 | ALMS Alumis | 1.37% | |
| 43 | AXSM Axsome Therapeutics | 1.37% | |
| 44 | LQDA Liquidia | 1.33% | |
| 45 | CRMD CorMedix | 1.33% | |
| 46 | WVE Wave Life Sciences | 1.3% | |
| 47 | PAHC Phibro Animal Health | 1.28% | |
| 48 | OCUL Ocular Therapeutix | 1.19% | |
| 49 | RAPP Rapport Therapeutics | 1.18% | |
| 50 | ANRO Alto Neuroscience | 1.14% | |
| 51 | AQST Aquestive Therapeutics | 1.04% | |
| 52 | PHAT Phathom Pharmaceuticals | 0.95% | |
| 53 | ACRS Aclaris Therapeutics | 0.84% | |
| 54 | RLMD Relmada Therapeutics | 0.82% | |
| 55 | AVLN Avalyn Pharma Inc | 0.79% | |
| 56 | ARVN Arvinas | 0.74% | |
| 57 | EOLS Evolus | 0.68% | |
| 58 | LXRX Lexicon Pharmaceuticals | 0.66% | |
| 59 | BIOA Bioage Labs Inc | 0.55% | |
| 60 | CTNM Contineum Therapeutics | 0.44% | |
| 61 | EYPT EyePoint | 0.08% |
The most recent file State Street SPDR has published for XPH is dated 2026-10-27, 1 day before these prices, which is the median for the State Street SPDR ETFs covered here. Every one of the 61 positions XPH holds, with its weight, is in the fund's JSON file. See the other 16 ETFs with a page here that hold MANE, and how their weights compare with the 2.86% XPH gives it.
Category: Health Care, set by TickerInside from the ETF's own latest file. In its file of 2026-10-27, 100% of its stocks whose sector is known are health care companies, each in the sector the site gives that company. How categories are set.
https://tickerinside.com/api/v1/fund/xph.jsonhttps://tickerinside.com/api/v1/fund/xph.csv=IMPORTDATA("https://tickerinside.com/api/v1/fund/xph.csv")If your sheet uses a decimal comma: =IMPORTDATA("https://tickerinside.com/api/v1/fund/xph.csv"; ","; "en_US")curl -s https://tickerinside.com/api/v1/fund/xph.jsonHow much money went into or out of XPH?
On the close of Friday, October 23, 2026, XPH neither created nor redeemed shares. Over its last 5 closes, a net outflow of $9.5 million.
From XPH's own holdings files. Every ETF's latest flows.
How is XPH split by sector and country?
| Sector | Weight | Weight bar |
|---|---|---|
| Health care | 99.9% |
| Country | Weight | Weight bar |
|---|---|---|
| United States | 98.0% | |
| Canada | 2.0% |
From its SPDR file of 2026-10-27. How these are measured.
What did XPH hold in its SEC reports since 2019?
In XPH's SEC filings, its largest position went from HZNP at 4.87% on 2019-09-30 to Definium Therapeutics, Inc. (DFTX) at 3.09% on 2026-06-30, across 28 quarterly reports.
| Report | Positions | Largest | Top 10 |
|---|---|---|---|
| 2019-09-30 | 38 | HZNP 4.87% | 47.0% |
| 2019-12-31 | 39 | AXSM 4.84% | 44.4% |
| 2020-12-31 | 42 | RPRX 4.94% | 44.8% |
| 2021-12-31 | 47 | LLY 4.78% | 45.8% |
| 2022-12-31 | 41 | PRGO 4.68% | 44.4% |
| 2023-12-31 | 35 | OGN 5.35% | 46.5% |
| 2024-12-31 | 45 | TARS 3.89% | 36.9% |
| 2025-12-31 | 59 | AXSM 2.28% | 20.6% |
| 2026-06-30 | 65 | DFTX 3.09% | 22.2% |
The first report, then the last of each year, of the 28 reports XPH filed on SEC Form N-PORT from 2019-09-30 to 2026-06-30, each company under its ticker today. Every position of every report is in its quarterly file, and at any date at /api/v1/history/xph/{date}.json. How these are read.
What does XPH share with other ETFs?
The ETF nearest to XPH is IHE: the two hold 39.9% of their weight in common, in the 53 companies both own, and 91.9% of XPH itself is also held there. No covered ETF holds more than that in common with XPH; it duplicates nothing here closely.
| ETF | Overlap by weight | Of XPH held there | Of that ETF in XPH | Companies in both | Overlap bar |
|---|---|---|---|---|---|
| IHE | 39.9% | 91.9% | 100.0% | 53 | |
| PJP | 37.0% | 37.0% | 65.1% | 19 | |
| PSCH | 17.5% | 29.5% | 18.9% | 15 | |
| PPH | 16.6% | 25.7% | 49.8% | 13 | |
| VHT | 12.6% | 82.4% | 33.8% | 48 | |
| IYH | 12.2% | 25.7% | 36.5% | 13 | |
| XLV | 11.2% | 14.9% | 36.6% | 7 | |
| RSPH | 11.2% | 14.9% | 11.3% | 7 | |
| CANC | 11.0% | 11.9% | 17.2% | 7 | |
| IXJ | 10.3% | 14.9% | 25.9% | 7 | |
| IBBQ | 9.3% | 67.2% | 9.3% | 42 | |
| PTH | 8.7% | 11.9% | 8.7% | 7 |
PPH's holdings are from its SEC Form N-PORT for the period ended 2026-06-30, filed 2026-08-26. The holdings of VHT and CANC are from their SEC Form N-PORT filings for the period ended 2026-05-31, filed 2026-07-29. The other ETFs' holdings are from their issuers' latest files. Check XPH against any ETF in the ETF overlap calculator · how overlap is measured.
What adds something different to XPH?
MCHI shares 0% of weight with XPH and its weekly returns correlate with it at 0.27 over three years. The table lists the covered ETFs with the least in common with XPH, least shared weight first and, among equals, lowest correlation.
| ETF | Name | Overlap by weight | Correlation, 3y | Companies in both |
|---|---|---|---|---|
| MCHI | iShares MSCI China ETF | 0.0% | 0.27 | 0 |
| RING | iShares MSCI Global Gold Miners ETF | 0.0% | 0.30 | 0 |
| SOXX | iShares Semiconductor ETF | 0.0% | 0.32 | 0 |
| SLVP | iShares MSCI Global Silver and Metals Miners ETF | 0.0% | 0.32 | 0 |
| PICK | iShares MSCI Global Metals & Mining Producers ETF | 0.0% | 0.47 | 0 |
| PFF | iShares Preferred and Income Securities ETF | 0.0% | 0.48 | 0 |
| SCZ | iShares MSCI EAFE Small-Cap ETF | 0.0% | 0.55 | 0 |
| USRT | iShares Core U.S. REIT ETF | 0.0% | 0.55 | 0 |
Cost, returns and risk
| Expense ratio | 0.35% |
|---|---|
| Dividend yield | 0.42% |
| Total return, 1 year | 30.6% |
| Total return, 3 years cumulative | 78.7% |
| Total return, 5 years cumulative | 32.6% |
| Volatility, annualised | 19.9% |
| Worst fall, 3 years | -21.1% |
| Beta against SPY, 3 years of weekly returns | 0.74 |
| Weight in the ten largest positions | 24.3% |
| Largest single position | 2.9% |
| Assets under management | $0.5B |
Expense ratio, yield and assets are reference data (the expense ratio from XPH's SEC filing of 2026-10-26); the weight in the ten largest positions and the largest single position are from the issuer file of 2026-10-27; every other figure is computed here from weekly closes.
How it moves with the market
| Against | Correlation, 3 years | Covariance, annualised, in percent squared |
|---|---|---|
| SPY | 0.52loosely linked | 143 |
| QQQ | 0.39barely linked | 149 |
Weekly total returns. What the bands mean · why the covariance is printed.
Year by year
| Year | Total return |
|---|---|
| 2026 | 15.6% |
| 2025 | 31.6% |
| 2024 | 4.9% |
| 2023 | 3.0% |
| 2022 | -9.8% |
One year
Where to go next
- ARKG, ARK Genomic Revolution ETF
- BBH, VanEck Biotech ETF
- BMED, iShares Health Innovation Active ETF
- CANC, Tema Oncology ETF
- Run a portfolio x-ray to see what XPH carries once you look through it
- Compare XPH against any other ETF in the builder
Holdings from the most recent file State Street SPDR has published, dated 2026-10-27. Prices through 2026-10-28. How every figure here is produced. Measurements, not investment advice.
Cite this page
TickerInside, State Street SPDR S&P Pharmaceuticals ETF (XPH), holdings from the issuer's file of 2026-10-27, https://tickerinside.com/etf/xph/, CC BY 4.0
<a href="https://tickerinside.com/etf/xph/">TickerInside</a> (https://tickerinside.com/etf/xph/)